Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of <scp>TAK</scp>‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects

Jenkins, Helen; Sakurai, Yuichi; Nishimura, Akira; Okamoto, Hiroyuki; G. Hibberd, Mark; O. Jenkins, Richard; Yoneyama, Tomoki; Ashida, Kiyoshi; Ogama, Yoichiro; Warrington, Steve

doi:10.1111/apt.13121

Public

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects

Published in Alimentary Pharmacology & Therapeutics • Feb 23, 2015

Authors:

Helen Jenkins

Yuichi Sakurai

Akira Nishimura

Abstract

BACKGROUND: TAK-438 (vonoprazan) is a potassium-competitive acid blocker that reversibly inhibits gastric H(+) , K(+) -ATPase. AIM: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-438 in healthy Japanese and non-Japanese men. METHODS: In two Phase I, randomised, do...

Subject

Tolerability

Pharmacokinetics

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!